About Ral GTPase-activating protein subunit alpha-2
Ral GTPase-activating protein subunit alpha-2 (RALGAPA2) is a protein
from Homo sapiens identified by UniProt accession
Q2PPJ7, 1873 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Ral GTPase-activating protein subunit alpha-2 |
|---|
| UniProt accession | Q2PPJ7 |
|---|
| Gene | RALGAPA2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1873 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (33)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.23
- squamous cell lung carcinoma · score 0.12
- head and neck squamous cell carcinoma · score 0.09
- diet measurement · score 0.08
- hepatocellular carcinoma · score 0.08
- body height · score 0.07
- neoplasm · score 0.07
- body weight · score 0.06
- DNA methylation · score 0.04
- autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2PPJ7-F1 | alphafold | PREDICTED | 72.19 | — |
Amino-acid sequence (1873 residues)
MFSRRSHGDV KKSTQKVLDP KKDVLTRLKH LRALLDNVDA NDLKQFFETN YSQIYFIFYE NFIALENSLK LKGNNKSQRE ELDSILFLFE KILQFLPERI FFRWHYQSIG STLKKLLHTG NSIKIRCEGI RLFLLWLQAL QTNCAEEQVL IFACLVPGFP AVMSSRGPCT LETLINPSPS VADVKIYPEE ITPLLPAISG EKIAEDQTCF FLQILLKYMV IQAASLEWKN KENQDTGFKF LFTLFRKYYL PHLFPSFTKL TNIYKPVLDI PHLRPKPVYI TTTRDNENIY STKIPYMAAR VVFIKWIVTF FLEKKYLTAT QNTKNGVDVL PKIIQTVGGG AVQERAPELD GGGPTEQDKS HSNSSTLSDR RLSNSSLCSI EEEHRMVYEM VQRILLSTRG YVNFVNEVFH QAFLLPSCEI AVTRKVVQVY RKWILQDKPV FMEEPDRKDV AQEDAEKLGF SETDSKEASS ESSGHKRSSS WGRTYSFTSA MSRGCVTEEE NTNVKAGVQA LLQVFLTNSA NIFLLEPCAE VPVLLKEQVD ACKAVLIIFR RMIMELTMNK KTWEQMLQIL LRITEAVMQK PKDKQIKDLF AQSLAGLLFR TLMVAWIRAN LCVYISRELW DDFLGVLSSL TEWEELINEW ANIMDSLTAV LARTVYGVEM TNLPLDKLSE QKEKKQRGKG CVLDPQKGTT VGRSFSLSWR SHPDVTEPMR FRSATTSGAP GVEKARNIVR QKATEVEECQ QSENAPAAGS GHLTVGQQQQ VLRSSSTSDI PEPLCSDSSQ GQKAENTQNS SSSEPQPIQE NKGHVKREHE GITILVRRSS SPAELDLKDD LQQTQGKCRE RQKSESTNSD TTLGCTNEAE LSMGPWQTCE EDPELNTPTD VVADADARHW LQLSPTDASN LTDSSECLTD DCSIIAGGSL TGWHPDSAAV LWRRVLGILG DVNNIQSPKI HARVFCYLYE LWYKLAKIRD NLAISLDNQS SPSPPVLIPP LRMFASWLFK AATLPNEYKE GKLQAYRLIC AMMTRRQDVL PNSDFLVHFY LVMHLGLTSE DQDILNTIIR HCPPRFFSLG FPGFSMLVGD FITAAARVLS TDILTAPRSE AVTVLGSLVC FPNTYQEIPL LQSVPEVNEA ITGTEDVKHY LINILLKNAT EEPNEYARCI AVCSLGVWIC EELAQCTSHP QVKEAINVIG VTLKFPNKIV AQVACDVLQL LVSYWEKLQM FETSLPRKMA EILVATVAFL LPSAEYSSVE TDKKFIVSLL LCLLDWCMAL PVSVLLHPVS TAVLEEQHSA RAPLLDYIYR VLHCCVCGSS TYTQQSHYIL TLADLSSTDY DPFLPLANVK SSEPVQYHSS AELGNLLTVE EEKKRRSLEL IPLTARMVMA HLVNHLGHYP LSGGPAILHS LVSENHDNAH VEGSELSFEV FRSPNLQLFV FNDSTLISYL QTPTEGPVGG SPVGSLSDVR VIVRDISGKY SWDGKVLYGP LEGCLAPNGR NPSFLISSWH RDTFGPQKDS SQVEEGDDVL DKLLENIGHT SPECLLPSQL NLNEPSLTPC GMNYDQEKEI IEVILRQNAQ EDEYIQSHNF DSAMKVTSQG QPSPVEPRGP FYFCRLLLDD LGMNSWDRRK NFHLLKKNSK LLRELKNLDS RQCRETHKIA VFYIAEGQED KCSILSNERG SQAYEDFVAG LGWEVDLSTH CGFMGGLQRN GSTGQTAPYY ATSTVEVIFH VSTRMPSDSD DSLTKKLRHL GNDEVHIVWS EHSRDYRRGI IPTAFGDVSI IIYPMKNHMF FIAITKKPEV PFFGPLFDGA IVSGKLLPSL VCATCINASR AVKCLIPLYQ SFYEERALYL EAIIQNHREV MTFEDFAAQV FSPSPSYSLS GTD
Explore Ral GTPase-activating protein subunit alpha-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets